DelveInsight has launched a new report on Postherpetic Neuralgia Pipeline Insight, 2020
“Postherpetic Neuralgia Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postherpetic Neuralgia market. A detailed picture of the Postherpetic Neuralgia pipeline landscape is provided, which includes the disease overview and Postherpetic Neuralgia treatment guidelines.
The assessment part of the report embraces in-depth Postherpetic Neuralgia commercial assessment and clinical assessment of the Postherpetic Neuralgia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postherpetic Neuralgia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Request for :- PHN free sample page
Pipeline Development Activities:-
The report provides insights into:
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Report Scope:-
Report Highlights:-
Key companies are working PHN are given below:-
1. Lateral Pharma Co.
2. Novartis Pharma Co
3. TEVA Pharma Co.
Name of drugs covered that are given below:-
1. LAT 8881
2. EMA 401
3. TV 45070
Table of contents
1. Report Introduction
2. Postherpetic Neuralgia
2.1. Overview
2.2. History
2.3. Postherpetic Neuralgia Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Postherpetic Neuralgia Diagnosis
2.6.1. Diagnostic Guidelines
3. Postherpetic Neuralgia Current Treatment Patterns
3.1. Postherpetic Neuralgia Treatment Guidelines
4. Postherpetic Neuralgia – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Postherpetic Neuralgia companies collaborations, Licensing, Acquisition -Deal Value Trends
5. Therapeutic Assessment
6. Postherpetic Neuralgia Late Stage Products (Phase-III)
7. Postherpetic Neuralgia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Postherpetic Neuralgia Discontinued Products
13. Postherpetic Neuralgia Product Profiles
14. Postherpetic Neuralgia Key Companies
15. Postherpetic Neuralgia Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Postherpetic Neuralgia Unmet Needs
18. Postherpetic Neuralgia Future Perspectives
19. Postherpetic Neuralgia Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
22. About Delveinsight
Related Reports:-
1. Postherpetic Neuralgia – Epidemiology Forecast to 2030
2. Postherpetic Neuralgia- Market Insight, Epidemiology and Market Forecast -2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/